Human Health Toxicity Assessment for Perfluorooctanoic Acid (PFOA)

January 2025
EPA Doc No. 822F25001

The chart below demonstrates that the PFOA exposure level expected to cause adverse noncancer effects on the immune system, development, the cardiovascular system, and the liver in humans (Point of Departure, **POD**) are similar. The chart also depicts the selected PODs with adjustments (Uncertainty Factors, **UF**) to be protective of at-risk populations and account for data gaps to derive **candidate reference doses (RfD)**. **Overall, or final, RfDs** are in orange.

Effects on the immune and cardiovascular systems, development, and the liver occur at the same or approximately the same doses of PFOA exposure in multiple studies, populations, and geographic locations, which increases confidence in the RfD.

